Imperial College London
Alternate

DrThiagarajahSasikaran

Faculty of Medicine, School of Public Health

Deputy Operations Manager
 
 
 
//

Contact

 

t.sasikaran

 
 
//

Location

 

Stadium House, 68 Wood LaneStadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Rodgers:2011:10.1371/journal.pone.0019857,
author = {Rodgers, A and Patel, A and Berwanger, O and Bots, M and Grimm, R and Grobbee, DE and Jackson, R and Neal, B and Neaton, J and Poulter, N and Rafter, N and Raju, PK and Reddy, S and Thom, S and Vander, Hoorn S and Webster, R},
doi = {10.1371/journal.pone.0019857},
journal = {PLOS One},
title = {An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill ("Polypill") in People with Raised Cardiovascular Risk},
url = {http://dx.doi.org/10.1371/journal.pone.0019857},
volume = {6},
year = {2011}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: There has been widespread interest in the potential of combination cardiovascular medications containingaspirin and agents to lower blood pressure and cholesterol (‘polypills’) to reduce cardiovascular disease. However, noreliable placebo-controlled data are available on both efficacy and tolerability.Methods: We conducted a randomised, double-blind placebo-controlled trial of a polypill (containing aspirin 75 mg,lisinopril 10 mg, hydrochlorothiazide 12.5 mg and simvastatin 20 mg) in 378 individuals without an indication for anycomponent of the polypill, but who had an estimated 5-year cardiovascular disease risk over 7.5%. The primary outcomeswere systolic blood pressure (SBP), LDL-cholesterol and tolerability (proportion discontinued randomised therapy) at 12weeks follow-up.Findings: At baseline, mean BP was 134/81 mmHg and mean LDL-cholesterol was 3.7 mmol/L. Over 12 weeks, polypilltreatment reduced SBP by 9.9 (95% CI: 7.7 to 12.1) mmHg and LDL-cholesterol by 0.8 (95% CI 0.6 to 0.9) mmol/L. Thediscontinuation rates in the polypill group compared to placebo were 23% vs 18% (RR 1.33, 95% CI 0.89 to 2.00, p = 0.2).There was an excess of side effects known to the component medicines (58% vs 42%, p = 0.001), which was mostly apparentwithin a few weeks, and usually did not warrant cessation of trial treatment.Conclusions: This polypill achieved sizeable reductions in SBP and LDL-cholesterol but caused side effects in about 1 in 6people. The halving in predicted cardiovascular risk is moderately lower than previous estimates and the side effect rate ismoderately higher. Nonetheless, substantial net benefits would be expected among patients at high risk.
AU  - Rodgers,A
AU  - Patel,A
AU  - Berwanger,O
AU  - Bots,M
AU  - Grimm,R
AU  - Grobbee,DE
AU  - Jackson,R
AU  - Neal,B
AU  - Neaton,J
AU  - Poulter,N
AU  - Rafter,N
AU  - Raju,PK
AU  - Reddy,S
AU  - Thom,S
AU  - Vander,Hoorn S
AU  - Webster,R
DO  - 10.1371/journal.pone.0019857
PY  - 2011///
SN  - 1932-6203
TI  - An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill ("Polypill") in People with Raised Cardiovascular Risk
T2  - PLOS One
UR  - http://dx.doi.org/10.1371/journal.pone.0019857
UR  - http://hdl.handle.net/10044/1/29545
VL  - 6
ER  -
Download